evipedia.ai
← Back

SAMe for Health & Longevity

Created on 11/03/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

SAMe, a compound the body already makes to tag DNA, proteins and brain chemicals, is sold as a dietary supplement and studied mainly for depression, osteoarthritis and liver disease. Taken alone, it outperformed placebo for depression in pooled studies, but studies disagree and research quality is modest. No human study has tested it for slowing aging. Main hazards: mania in bipolar-prone people and combining it with certain antidepressants. (Full Review)

Protocol

Depression, SAMe alone
1,600–3,200 mg daily
Earlier trials used 200–1,600 mg daily. No longevity dose exists.
Depression, add-on to SSRIs
800 mg twice daily
For 6 weeks in SSRI non-responders
Single or split dosing
Usually two or three doses daily
For daily totals above 400 mg, given the 1.7-hour half-life; common practice favors morning and early afternoon, since late dosing may disturb sleep
Time to effect
Depression
From week 1
At one site; trials typically ran 6–12 weeks
Liver time course and industry links
Within 2 weeks
Liver-enzyme falls in cholestasis, per a review co-authored by an Abbott employee
Osteoarthritis
By the second month
Slower than celecoxib, then matching it

Benefits

Contraindications
  • People with bipolar disorder or a history of mania (unless under psychiatric supervision)
  • People with Parkinson's disease taking levodopa (unless supervised)
  • Immunocompromised people (e.g., HIV infection)
  • Pregnant or breastfeeding women outside medical supervision (especially in the first trimester)
  • People with inherited methionine-cycle defects causing homocystinuria or high homocysteine (e.g., cystathionine beta-synthase deficiency, vitamin B12-metabolism defects)
    •
Key Interactions
  • Serotonergic antidepressants (clomipramine, sertraline, escitalopram): serotonin-syndrome-like toxicity; mania
  • Food: delayed peak levels; exposure raised or cut depending on the tablet
  • L-tryptophan and tryptophan-containing products: possible serotonin toxicity
    •
Theoretical (inferred from mechanism)
  • Levodopa (Parkinson's disease): weaker levodopa effect
  • Other serotonergic drugs (tramadol, triptans such as sumatriptan for migraine): serotonin toxicity
  • Over-the-counter dextromethorphan (cough suppressant): serotonin toxicity
  • Serotonergic supplements (St. John's wort, 5-HTP): serotonin toxicity
  • Other mood-active supplements (omega-3 rich in EPA, L-methylfolate, saffron): hypomania in bipolar-prone people
  • B vitamins and methyl donors (folate, vitamin B12, vitamin B6, betaine): support recycling of SAMe-derived homocysteine
  • Creatine: may spare SAMe
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Gastrointestinal discomfort and bleeding; mania or hypomania in bipolar disorder; increased anxiety and agitation; headache; insomnia, itching and hypersensitivity reactions; weakness and dizziness; fluid retention and swelling; uncommon label-listed reactions
    •
  • Speculative: Homocysteine and SAH elevation; excess SAMe disrupting methylation; growth signaling counter to longevity pathways; Pneumocystis infection in immunocompromised people
    •

Monitoring

Marker Target Why
Plasma total homocysteine About 5–15 µmol/L Safety check: SAMe is converted to homocysteine
Vitamin B12 and folate (serum) B12 about 200–900 pg/mL; folate above about 3 ng/mL Safety check: deficiency impairs homocysteine recycling
ALT and AST (liver enzymes) ALT about 7–56 U/L; AST about 8–48 U/L Liver response; safety check
Serum creatinine and urea Creatinine about 0.6–1.3 mg/dL; urea nitrogen about 7–20 mg/dL Safety check: kidney function in long-term use
PHQ-9 depression score No established target; track change from own baseline Mood response

Cadence: Baseline before starting; mood and side-effect check at 2 and 6 weeks; homocysteine and liver enzymes at 3 months, then every 6–12 months; kidney markers during long-term use; elevated mood, agitation, tremor or fever prompts immediate review

Qualitative Assessment

  • Mood stability and motivation
  • Energy and daytime alertness
  • Sleep onset and quality
  • Gastrointestinal comfort
  • Joint pain and morning stiffness, when osteoarthritis is the target
  • Early signs of hypomania, such as reduced need for sleep or racing thoughts
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.